NCT03880539View on ClinicalTrials.gov

Bezlotoxumab (BEZLO) In Addition To Standard Of Care (SOC) Vancomycin For The Treatment of Multi-Recurrent Clostridium Difficile Infection

PHASE4CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

June 25, 2019

Primary Completion Date

November 18, 2021

Study Completion Date

November 18, 2021

Conditions
Clostridium Difficile Infection Recurrence
Interventions
DRUG

bezlotoxumab

Adding BEZLO to SOC oral VAN pulse/taper

DRUG

Vancomycin Oral

SOC vancomycin pulse/taper

Trial Locations (1)

66160

University of Kansas Medical Center, Kansas City

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of Kansas Medical Center

OTHER

NCT03880539 - Bezlotoxumab (BEZLO) In Addition To Standard Of Care (SOC) Vancomycin For The Treatment of Multi-Recurrent Clostridium Difficile Infection | Biotech Hunter | Biotech Hunter